ClinicalTrials.gg
RecruitingNCT06378736Updated Nov 6, 2026

Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus

An observational study in Systemic Lupus Erythematosus, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Northwell Health · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 6, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Planned enrollment
52nd of 67
40 · median 223
Started
2024
with 32 others
Observational
68 of 477
21 open now
Primary completion
2028-03
later than 66 of 125 live
Registered
400th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 52nd largest by planned enrollment of the 67 observational ones that give a count, is one of 33 that started in 2024, is one of 68 observational ones, reaches primary completion later than 66 of the 125 other live ones, and was the 400th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

Patients with systemic lupus erythematosus (SLE) often experience a frustrating decline of their cognitive skills that includes considerable problems in attention, learning, and memory. This lupus-related cognitive dysfunction (termed SLE-CD) is recognized as the most prevalent of the nineteen neuropsychiatric SLE syndromes, as it affects up to 80% of patients and can significantly decrease their quality of life. The goal is to have tools that can be used for diagnosis and for monitoring responses after targeted interventions and therapies. This study will focus on electroencephalographic (EEG) signals, which will be detected noninvasively from scalp placed surface electrodes while the subjects are in a state of wakeful rest. Our hypothesis is that a subset of brain oscillations known as theta and gamma, and their co-modulation or coupling will be disrupted in SLE patients. This research protocol will subject patients with systemic lupus erythematosus (SLE) to scalp electroencephalography (EEG), with the goal of determining whether specific EEG patterns ('theta-gamma coupling') appear abnormal during wakeful-rest periods of 20 minutes. The investigators are interested in using scalp EEG because it is a standard, safe and robust technique for monitoring the electrophysiological activity of neurons in the cerebral cortex.

Read the detailed description

Patients will sit comfortably in a quiet room in a wakeful state and perform simple operations with toy blocks and look at three dimensional objects and answer some questions. The EEG electrodes fit into a custom-made cap and will effectively transmit wave activity just by touching the skin surface of the scalp. There is no need for electrode paste so at the end of the experiment the patient can remove the cap and go home. The entire procedure including fitting of the EEG cap will take about an hour.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Twenty of the SLE subjects that have participated in prior brain imaging studies. The other 20 SLE subjects will be recruited from 2 ongoing observational studies of brain involvement in SLE.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be able to understand and provide .
  2. Must be ≥18 and ≤65years of age.
  3. Must be female.
  4. Must fulfill the 1997 American College of Rheumatology (ACR) revised criteria for the diagnosis of SLE or the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Criteria for SLE.
  5. Must have stable disease activity and medication doses for 4 weeks prior to screening. Stable disease activity is defined as no increase in disease activity requiring an increase or change in medications.
  6. Must be on a dose that is ≤ prednisone 10 mg daily, or equivalent.
  7. Must have demonstrated significantly increased metabolism in the hippocampus, temporal or parietal lobes on prior fluoro-deoxy glucose (FDG)-PET imaging.

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness to give written or comply with study protocol.
  2. History of neurological diseases including, but not limited to, severe head injury or history of brain surgery, stroke, seizure, toxic exposure, mental retardation, migraine headaches, multiple sclerosis, dementia.
  3. History of documented within 6 months of screening.
  4. History of illicit drug or alcohol dependence/abuse within the past 12 months.
  5. Current use of antipsychotic, anticonvulsant, antidepressant (except for selective serotonin reuptake inhibitors) or anxiolytic medications (short acting anxiolytic medications are allowed if taken as needed with > 5 half-lives prior to assessments).
  6. History of chronic pain; current and/or chronic use of narcotic analgesia for > 21 days (total) within the last 3 months, or last dose less than 5 days prior to assessment.
  7. Increased disease activity within 4 weeks of screening defined by an increase in SLEDAI by 3 points or more, exclusive of points from serologies, which prompts an increase in or new addition of SLE medications.
  8. History of a diagnosis of a primary psychiatric disorder preceding SLE diagnosis.
  9. Current active acute infections requiring antibiotics within 2 weeks of screening and chronic known infections (eg. , C, and/or ).
  10. Co-existing other disease(s) other than autoimmune thyroid disease and secondary Sjogren's Syndrome.
  11. The presence of uncontrolled, severe hypertension, diabetes or heart disease.
  12. Impaired renal function with an estimated (eGFR)\< 30.
  13. Presence of any active medical condition that in the opinion of the investigator may contribute to cognitive and/or behavioral disturbances.
  14. Use of drugs within 30 days or 5 half-lives before the study visit, whichever is longer.
  15. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
  16. Current treatment with cyclophosphamide, addition of belimumab within 4 months, addition of any disease modifying drug or biologic within 3 months of screening, and/or rituxan within 6 months.
  17. Limited fluency with English or Spanish that in the opinion of the investigator would limit the subject's performance on the assessments.
  18. Pregnant and/or lactating women.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherElectroencephalography (EEG) signals, which will be detected noninvasively from dry scalp surface electrodes while the subjects are in a state of wakeful rest.

    The proposed study is to determine whether EEG signals, namely theta-gamma coupling (TGC); The investigators are testing whether TGC can be used as a non-invasive novel biomarker in diagnosis and monitoring of insidious and difficult to detect cognitive dysfunction in SLE patients.

06

What researchers measure

Primary outcomes

  1. A measure of the amount and relationship of theta and gamma waves in the EEG recording. The ability to perform the block building task and the ability to choose among unfolded three-dimensional objects.

    Patient will build with toy blocks and three dimensional combination will suffice. The patient will also observe three dimensional objects - cubes, for example, that are unfolded and choose a matching object from an array that includes the object and three foils. EEG activity will be recorded during this period. As the subjects will be fitted with noninvasive EEG caps (using dry electrodes that will contact the scalp directly) which will record the ongoing brain activity while the subjects, in a wakeful resting mode attempt to build with the toy blocks and analyze the three dimensional figures. This activity will go on for approximately 20 minutes. The EEG signals will be analyzed to determine the theta gamma coupling (TGC).

    Time frame: Aim 1 will take the first 24 patients and they will spend an hour and a half undergoing EEG measuring TGC. For Aim 2 the patients will undergo EEG measuring TGC and predict the subsequent PET scan - which will occur under a separate protocol.

07

Study locations

1 of 1 sites recruiting
  • Northwell Health-Feinstein Insitute
    Manhasset, New York 11030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The investigators will make recordings available to qualified researchers and pay attention to keep protected health information (PHI) confidential.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After the complete analysis of the patient groups and after complete analysis of the healthy control group.

Access criteria: To be determined.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2028, 47 months after the start.

Of 90 non-industry observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 212. This study's planned 47 months is below that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 30 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Jan 2024 → Apr 2024, primary completion Mar 2026 → Mar 2028 and completion Mar 2026 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 22, 2024
StartActual
Apr 22, 2024was Jan 2024
Primary completionEst.
Mar 23, 2028was Mar 2026
CompletionEst.
Mar 23, 2028was Mar 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 22, 2024→Apr 22, 2024
Nov 6, 2026
Primary completion
Mar 23, 2026→Mar 23, 2028
Nov 6, 2026
Study completion
Mar 23, 2026→Mar 23, 2028
Nov 6, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAim 1 ONLY: Must have demonstrated significantly increased metabolism in the hippocampus, temporal or parietal lobes on prior fluoro-deoxy glucose (FDG)-PET imaging.
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Jan 22, 2024→Apr 22, 2024
    Primary completion Mar 23, 2026→Mar 23, 2028
    Study completion Mar 23, 2026→Mar 23, 2028
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAim 1 ONLY: Must have demonstrated significantly increased metabolism in the hippocampus, temporal or parietal lobes on prior fluoro-deoxy glucose (FDG)-PET imaging.
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06378736
Lead sponsor
Northwell Health
Responsible party
Bruce Volpe (Professor, Investigator, Northwell Health) — Principal investigator
First posted
Apr 22, 2024
Start date
Apr 22, 2024
Primary completion
Mar 23, 2028 (estimated)
Completion
Mar 23, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Bruce T Volpe, MD
Contact
bvolpe1@northwell.edu
5165623384

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion